Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
Akebia Therapeutics (Nasdaq: AKBA) announced that CEO John P. Butler and CFO/CBO Erik Ostrowski will participate in one-on-one investor meetings at the Wells Fargo Healthcare Conference in Boston, held September 8–10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) announced that CEO John P. Butler and CFO/CBO Erik Ostrowski will participate in one-on-one investor meetings at the Wells Fargo Healthcare Conference in Boston, held September 8–10, 2026. Management plans to discuss Akebia’s commercial kidney disease products and its pipeline of clinical-stage programs.
Details
News Market Reaction – AKBA
On Sep 1, the day this news came out, AKBA closed 2.82% above the previous close.
Data tracked by StockTitan Argus for the Sep 1 session.
Key Figures
- Announcement date
- September 01, 2026
- News announcement
- Conference dates
- September 8 10, 2026
- Wells Fargo Healthcare Conference in Boston
- Founded
- 2007
- Akebia Therapeutics
Historical Context
-
Revenue declined and the company posted a net loss; Vafseo growth partially offset weakness.
-
Two employees received inducement options covering 61,000 shares at a $1.32 exercise price.
-
Initiated an open-label Phase 2 basket trial of ebribafusp in rare kidney diseases.
-
Announced the August 5 release date and 4:30 p.m. EDT conference call.
-
Three employees received inducement awards covering 125,600 shares at $1.14 per share.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, which will take place in Boston, September 8 – 10, 2026.
During meetings, management will discuss its commercial products and its robust pipeline of clinical stage kidney disease programs.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.